NCR3 and neuroblastoma: The authors conclude that NK cell modulating immunotherapeutics offer a promising strategy for treating NB patients and that antibodies neutralizing sB7-H6 serum molecules and antibodies targeting NKp30 are worth pursuing in future clinical development.